Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Financing Activities (2016 - 2025)

Ani Pharmaceuticals' Cash from Financing Activities history spans 16 years, with the latest figure at -$4.6 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 5.52% year-over-year to -$4.6 million; the TTM value through Dec 2025 reached -$9.9 million, down 103.75%, while the annual FY2025 figure was -$9.9 million, 103.75% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$4.6 million at Ani Pharmaceuticals, down from $6.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $291.0 million in Q3 2024 and bottomed at -$19.7 million in Q1 2024.
  • The 5-year median for Cash from Financing Activities is -$1.6 million (2024), against an average of $25.6 million.
  • The largest annual shift saw Cash from Financing Activities surged 8226.99% in 2021 before it tumbled 2246.06% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at $179.4 million in 2021, then plummeted by 100.28% to -$508000.0 in 2022, then crashed by 2246.06% to -$11.9 million in 2023, then skyrocketed by 58.83% to -$4.9 million in 2024, then grew by 5.52% to -$4.6 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Cash from Financing Activities are -$4.6 million (Q4 2025), $6.3 million (Q3 2025), and -$1.7 million (Q2 2025).